Larimar Therapeutics, Inc.
LRMR
$4.36
$0.092.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.70% | 52.62% | -30.99% | -82.23% | 10.58% |
| Total Depreciation and Amortization | -3.13% | -26.44% | -1.14% | 1.15% | -1.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.21% | 37.32% | -5.03% | 7.50% | 26.99% |
| Change in Net Operating Assets | 22.38% | -174.81% | 29.08% | 222.51% | 231.70% |
| Cash from Operations | 1.31% | -15.80% | -33.99% | -48.36% | 26.97% |
| Capital Expenditure | -- | -- | 100.00% | -21.05% | 61.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -240.62% | -14.71% | 2.90% | 75.19% | 30.10% |
| Cash from Investing | -241.07% | -14.71% | 2.97% | 75.24% | 30.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.40% | 53,888.56% | -100.31% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -192.30% | 2,056.45% | -106.80% | 13,004.08% | 95.54% |